Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Anti-influenza neuraminidase monoclonal antibodies and uses thereof

Anti-influenza neuraminidase monoclonal antibodies and uses thereof

US Patent 11958895 · Granted Apr 16, 2024

Estimated economic value: $1,549,000 ⓘ

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Anti-influenza neuraminidase monoclonal antibodies and uses thereof2025
Anti-influenza neuraminidase monoclonal antibodies and uses thereof2025
Anti-influenza neuraminidase monoclonal antibodies and uses thereof2025
Anti-influenza neuraminidase monoclonal antibodies and uses thereof2025
Multivalent live-attenuated influenza vaccine for prevention and control of equi2025
Multivalent live-attenuated influenza vaccine for prevention and control of equi2023
Broadly neutralizing anti-influenza human monoclonal antibody and uses thereof2021
Broadly neutralizing anti-influenza human monoclonal antibody and uses thereof2021
Broadly neutralizing anti-influenza human monoclonal antibody and uses thereof2021
Broadly neutralizing anti-influenza human monoclonal antibody and uses thereof2021
Live-attenuated vaccine having mutations in viral polymerase for the treatment a2021
Human monoclonal antibodies to human endogenous retrovirus K envelope (HERV-K) a2021